Clinical trials: Stage 2 Hypertension
Pulmonary Arterial Hypertension
Oral CXA-10 in Pulmonary Arterial Hypertension
The main objective of this study is to evaluate the safety and tolerability of 12-week oral CXA-10 therapy in subjects with pulmonary arterial hypertension, with additional evaluation on the clinical efficacy of oral CXA-10 on…
- Trial name
- PAH (NCT04125745)
- Testing
- CXA-10
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gladwin, Mark, MD
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers
The purpose of this clinical study is to evaluate the pharmacokinetics and the safety after administration of BR1018 and coadministration of BR1018A and BR1018B in healthy volunteers
- Trial name
- NCT06889012
- Testing
- BR1018, BR1018A, BR1018B
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Stage 1 Hypertension, Stage 2 Hypertension
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.
- Trial name
- NCT01508026
- Testing
- Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3
- Where
- 413 sites in United States
- Volunteers
- 4,161 people
- Sponsor
- Forest Laboratories
Glaucoma, Open-Angle, Ocular Hypertension
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular…
- Trial name
- NCT00753168
- Testing
- OT-730 ophthalmic solution, timolol maleate ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Othera Pharmaceuticals
Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)
Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension
Hypothesis: The small molecule and metabolic modulator Dichloroacetate (DCA) is safe, tolerated as a potential therapy in patients with moderate or severe Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT01083524
- Testing
- Dichloroacetate Sodium
- Where
- 2 sites in Canada, United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Alberta
Intrahepatic Cholangiocarcinoma (Icc), HAIC
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
At present, the first-line treatment for patients with advanced unresectable intrahepatic cholangiocarcinoma is mainly systemic treatment, but the improvement in efficacy is limited and is not enough to meet the current clinical…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab
- Trial name
- HAIC-quad (NCT06859684)
- Testing
- Durvalumab, hepatic arterial infusion chemotherapy (HAIC), Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- West China Hospital
Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease…
- Trial name
- NCT07441278
- Testing
- NS-863 Low Dose, NS-863 High Dose
- Where
- 2 sites in United States, Japan
- Volunteers
- 177 people
- Sponsor
- NS Pharma, Inc.
Pulmonary Arterial Hypertension
Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Ubenimex is being developed for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) to improve exercise capacity and delay clinical worsening.
- Trial name
- LIBERTY2 (NCT02736149)
- Testing
- ubenimex
- Where
- 28 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Eiger BioPharmaceuticals
The Elderly (≥ 70 Years) With Essential Hypertension
Fimasartan in the Senior Subjects
The objective of this study is to confirm the noninferiority of the blood pressure lowering effect of fimasartan and evaluate its safety compared to perindopril in the elderly with essential hypertension.
- Trial name
- FITNESS (NCT03246555)
- Testing
- Fimasartan or Fimasartan/Hydrochlorothiazide, Perindopril or Perindopril/Indapamide
- Where
- South Korea
- Volunteers
- 241 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Stage 2 Hypertension
8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
To evaluate the efficacy and safety of the valsartan/aliskiren combination compared to valsartan alone in patients with Stage 2 hypertension.
- Trial name
- VANTAGE (NCT00809926)
- Testing
- Valsartan/aliskiren, Valsartan
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Novartis
Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1015" and co-administration of "BR1015-1" and "BR1015-2" under fed conditions in healthy volunteers
- Trial name
- NCT06008015
- Testing
- BR1015, BR1015-1, BR1015-2
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
The aim of present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2…
- Trial name
- NCT01983735
- Testing
- TELMINUVO Tab. (80/2.5mg), TELMINUVO Tab. (80/5mg), S-amlodipine 2.5mg
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Prehypertension
UH3 Phase - Mindfulness-Based Blood Pressure Reduction (MB-BP) : Stage 2a RCT
The primary aim is to identify the impacts of a behavioral intervention called "Mindfulness-Based Blood Pressure Reduction" (MB-BP) vs.
- Trial name
- MB-BP (NCT03859076)
- Testing
- MB-BP, Enhanced Usual Care Control
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Brown University
End Stage Renal Disease, Hypertension
Electronic Decision Support for Deprescribing in Patients on Hemodialysis
Dialysis patients are prescribed an average of 10-12 medications per day, from up to 4-5 different clinicians and have the heaviest pill burden of all chronic conditions given their degree of comorbidity.
- Conditions
- End Stage Renal Disease, Hypertension, Diabete Type 2, Renal Failure Chronic
- Trial name
- MedSafer-HD (NCT05585268)
- Testing
- Medication reconciliation supplemented with MedSafer and deprescribing brochures
- Where
- Canada
- Volunteers
- 195 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Essential Hypertension
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of…
- Trial name
- NCT00758524
- Testing
- LCI699, Eplerenone
- Where
- United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
- Trial name
- LEVEL (NCT05983250)
- Testing
- TNX-103
- Where
- 42 sites in United States, Canada
- Volunteers
- 230 people
- Sponsor
- Tenax Therapeutics, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension
- Trial name
- NCT00595101
- Testing
- PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle
- Where
- 13 sites in Japan
- Volunteers
- 117 people
- Sponsor
- Bausch & Lomb Incorporated
Hypertension, Portal, Ascites
Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents
For this study, the investigators will be collecting data based on patients' random selection to two different approved standard of care treatments for ascites: Subjects will get randomized into either Group A: Large Volume…
- Trial name
- NCT04315571
- Testing
- Gore® Viatorr® Endoprosthesis with controlled expansion, Large Volume Paracentesis with albumin infusion
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of California, Los Angeles
Idiopathic Intracranial Hypertension
Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.
Assessing the safety and effectiveness of a 11-βhydroxysteroid dehydrogenase type 1 inhibitor (AZD4017), in a placebo controlled trial, in acute idiopathic intracranial hypertension (IIH) IIH is a condition of young, overweight…
- Trial name
- IIH:DT (NCT02017444)
- Testing
- AZD4017
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University of Birmingham